Ms. Jessica Rae Nieuwboer PHARM.D.

Recommended Articles

• Chronic Inflammation May Enhance Sustained Delivery of New Muscular Dystrophy Therapy

  The Duchenne Muscular Dystrophy is a genetic disorder that is accompanied by symptoms of progressive muscle weakness and degeneration. Duchenne muscular dystrophy is caused by the absence of dystrophin, a protein that is responsible for keeping muscles cells intact, and accounts for one of the nine...

• How Can Multiple Myeloma Affect My Bones?

  What is Multiple Myeloma?Multiple myeloma is a blood cancer that is also known as hematologic cancer. It is characterized by the uncontrollable multiplication of a certain population of plasma cells (also known as malignant plasma cells, or myeloma cells). Plenty of similar antibodies, known as...

• Managing Symptomatic Endometriosis

  Endometriosis is known as a disease that affects women through their reproductive age. It is the most common cause of chronic pelvic pain,  usually beginning in adolescence. It is also one of the main causes of infertility among women. It is a complex condition with a great variability when it...

• Dealing with Multiple Sclerosis Fatigue

  Multiple sclerosis is a poorly understood autoimmune disease with a variety of symptoms, not all of which are felt by every person. Perhaps the most common symptom of MS is fatigue, and even that does not affect everyone equally.Tiredness and lassitudeFatigue can manifest itself either mentally or...

• Treatment of Pneumonia

  Pneumonia is a lung infection that may cause cough, fever, and problems in breathing. Pneumonia is the infection of your lung tissue. It is usually not a serious infection, but in some patients, such as those with a weakened immune system, it could be a fatal infection. For most people, pneumonia...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...